Evidence map›Paper›PMID 41973298›Full record

ArticleInternational journal of hematology2026

Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study.

Yuki Shimizu, Shinsuke Takagi, Maki Higuchi, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Daisuke Kaji, Aya Nishida and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuki ShimizuDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan. shinsukewwwtakagi@icloud.com.ORCID http://orcid.org/0000-0003-0441-393X
Maki HiguchiClinical Physiology Section, Department of Clinical Laboratory, Toranomon Hospital, Tokyo, Japan.
Mika KunoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Hideki AraokaOkinaka Memorial Institute for Medical Research, Tokyo, Japan.
Yuki Asano-MoriCenter for Long-Term Follow-Up for Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Atsushi WakeCenter for Long-Term Follow-Up for Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 1050001, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.

Indexed as

Cord Blood Stem Cell TransplantationHepatic Veno-Occlusive DiseasePolydeoxyribonucleotidesAdolescentAdultChildFemaleHumansMaleRetrospective StudiesdefibrotidePolydeoxyribonucleotidesCord blood transplantationDefibrotideLate-onsetSinusoidal obstraction syndrome

Identifiers

PMID41973298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.